Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) and Repare Therapeutics (NASDAQ:RPTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Volatility & Risk
Eton Pharmaceuticals has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Eton Pharmaceuticals and Repare Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eton Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
| Repare Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
Valuation & Earnings
This table compares Eton Pharmaceuticals and Repare Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eton Pharmaceuticals | $34.68 million | 10.19 | -$940,000.00 | ($0.22) | -61.64 |
| Repare Therapeutics | $66.52 million | 0.85 | -$93.80 million | ($2.00) | -0.66 |
Eton Pharmaceuticals has higher earnings, but lower revenue than Repare Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 21.6% of Repare Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Eton Pharmaceuticals and Repare Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eton Pharmaceuticals | -15.81% | -36.29% | -16.84% |
| Repare Therapeutics | -99.76% | -40.87% | -35.07% |
Summary
Eton Pharmaceuticals beats Repare Therapeutics on 8 of the 14 factors compared between the two stocks.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
About Repare Therapeutics
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
